Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300339 · ClinicalTrials.gov registry record · Phase 2
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 599
- Enrollment target
NCT00300339 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 599 participants.
The verdict
NCT00300339, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 599 participants
- Enrollment target
Study Summary
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol
Interventions
- DRUG SL650472, Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300339
The ClinicalTrials.gov registry entry for NCT00300339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SL650472, Clopidogrel is the first listed.
NCT00300339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300339 about?
NCT00300339 is a clinical study titled "Mixed Antagonist of Serotonin for Claudication Optimal Therapy". To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cil...
What is the current status of trial NCT00300339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 599 participants. The study started on 2006-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00300339?
The interventions under investigation include: SL650472, Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00300339?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.